• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

    11/14/24 5:45:17 PM ET
    $SPRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SPRB alert in real time by email
    SC 13G/A 1 tm2427620d30_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Spruce Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    85209E109

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
       
    x Rule 13d-1(c)
       
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   85209E109
    1.

    Names of Reporting Persons

    5AM Opportunities II, L.P.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    1,773,000 shares (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    1,773,000 shares (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,773,000 shares (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.1% (3)

    12.

    Type of Reporting Person (See Instructions)

    PN

             

    (1)This Schedule 13G is filed by 5AM Opportunities II, L.P. (“Opps II”), 5AM Opportunities II (GP), LLC (“Opps II GP”), Dr. Kush Parmar (“Parmar”) and Andrew J. Schwab (“Schwab” and, with Opps II, Opps II GP and Parmar, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.

    (3)This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

     

    2 

     

     

    CUSIP No.   85209E109
    1.

    Names of Reporting Persons

    5AM Opportunities II (GP), LLC

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    1,773,000 shares (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    1,773,000 shares (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,773,000 shares (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.1% (3)

    12.

    Type of Reporting Person (See Instructions)

    OO

             

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.

    (3)This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

     

    3 

     

     

    CUSIP No.   85209E109
    1.

    Names of Reporting Persons

    Dr. Kush Parmar

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    1,773,000 shares (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    1,773,000 shares (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,773,000 shares (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.1% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

             

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.

    (3)This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

     

    4 

     

     

    CUSIP No.   85209E109
    1.

    Names of Reporting Persons

    Andrew J. Schwab

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
     

    (a)

    (b)

    ¨

    x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    0

    6.

    Shared Voting Power

    1,773,000 shares (2)

    7.

    Sole Dispositive Power

    0

    8.

    Shared Dispositive Power

    1,773,000 shares (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,773,000 shares (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    4.1% (3)

    12.

    Type of Reporting Person (See Instructions)

    IN

             

    (1)This Schedule 13G is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.

    (3)This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

     

    5 

     

     

    Item 1.
     
      (a)

    Name of Issuer

     

    Spruce Biosciences, Inc.

      (b)

    Address of Issuer’s Principal Executive Offices

     

    611 Gateway Boulevard, Suite 740

    South San Francisco, CA 94080

     
    Item 2.
     
      (a)

    Name of Person Filing

     

    5AM Opportunities II, L.P. (“Opps II”)

    5AM Opportunities II (GP), LLC (“Opps II GP”)

    Dr. Kush Parmar (“Parmar”)

    Andrew J. Schwab (“Schwab”)

      (b)

    Address of Principal Business Office or, if none, Residence

     

    c/o 5AM Ventures

    4 Embarcadero Center, Suite 3110

    San Francisco, CA 94111

      (c) Citizenship    
             
        Entities: Opps II - Delaware
          Opps II GP - Delaware
        Individuals: Parmar - United States
          Schwab - United States

      (d)

    Title of Class of Securities

     

    Common Stock, par value $0.0001 per share par value (“Common Stock”)

      (e)

    CUSIP Number

     

    85209E109

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable

     

    6 

     

     

     
    Item 4. Ownership

     

    The following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 is provided as of November 14, 2024:

     

    Reporting
    Persons
      Shares Held
    Directly
       Sole
    Voting
    Power
       Shared
    Voting
    Power
       Sole
    Dispositive
    Power
       Shared
    Dispositive
    Power
       Beneficial
    Ownership
       Percentage
    of Class (2)
     
    Opps II (1)   1,773,000    0    1,773,000    0    1,773,000    1,773,000    4.1%
    Opps II GP (1)   0    0    1,773,000    0    1,773,000    1,773,000    4.1%
    Parmar (1)   0    0    1,773,000    0    1,773,000    1,773,000    4.1%
    Schwab (1)   0    0    1,773,000    0    1,773,000    1,773,000    4.1%

     

    (1)Includes 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II that are currently exercisable. Opps II GP is the sole general partner of Opps II and Parmar and Schwab are the managing members of Opps II GP. Each of Opps II GP, Parmar and Schwab share voting and dispositive power over the shares held by Opps II.

    (2)This percentage is calculated based upon the sum of (i) 41,302,599 shares of the Common Stock issued and outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and (ii) 1,773,000 shares of Common Stock issuable upon exercise of warrants held by Opps II.

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   x
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Not applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    7 

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    5AM Opportunities II, L.P.  
         
    By: 5AM Opportunities II (GP), LLC  
    its General Partner  
         
    By: /s/ Kush Parmar  
        Name: Dr. Kush Parmar  
        Title: Managing Member  
         
    5AM Opportunities II (GP), LLC  
         
    By: /s/ Kush Parmar  
        Name: Dr. Kush Parmar  
        Title: Managing Member  

     

    /s/ Kush Parmar  
    Dr. Kush Parmar  
       
    /s/ Andrew J. Schwab  
    Andrew J. Schwab  

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

    8 

     

     

    Exhibit(s):

     

    AJoint Filing Agreement

     

    9 

     

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Spruce Biosciences, Inc. is filed on behalf of each of us.

     

    Dated: November 14, 2024

     

    5AM Opportunities II, L.P.  
         
    By: 5AM Opportunities II (GP), LLC  
    its General Partner  
         
    By: /s/ Kush Parmar  
        Name: Dr. Kush Parmar  
        Title: Managing Member  
         
    5AM Opportunities II (GP), LLC  
         
    By: /s/ Kush Parmar  
        Name: Dr. Kush Parmar  
        Title: Managing Member  

     

    /s/ Kush Parmar  
    Dr. Kush Parmar  
       
    /s/ Andrew J. Schwab  
    Andrew J. Schwab  

     

     

     

    Get the next $SPRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SPRB

    DatePrice TargetRatingAnalyst
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    12/11/2024Outperform → Perform
    Oppenheimer
    3/14/2024Buy → Neutral
    Guggenheim
    3/14/2024$9.00 → $2.00Outperform → Market Perform
    Leerink Partners
    3/14/2024$9.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    3/14/2024Buy → Neutral
    Ladenburg Thalmann
    3/14/2024Buy → Neutral
    H.C. Wainwright
    2/21/2024$10.00Buy
    Guggenheim
    More analyst ratings

    $SPRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market

      Relisting Contingent Upon Stockholder Approval of Reverse Stock Split Trading on Nasdaq Capital Market Anticipated to Commence On or Before August 5, 2025 Spruce Biosciences, Inc. (OTC:SPRB) ("Spruce"), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced that it has received approval from The Nasdaq Stock Market LLC ("Nasdaq") to resume trading of its common stock on the Nasdaq Capital Market subject to Spruce regaining compliance with Nasdaq's minimum bid price requirement on or before August 5, 2025. "We are pleased by Nasdaq's decision to lift its trading suspensio

      6/12/25 8:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Biologics License Application (BLA) Submission to U.S. FDA for TA-ERT Expected in 1H 2026 Spruce Biosciences, Inc. (OTC:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. "With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by t

      5/6/25 4:01:00 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

      Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). "This is truly a transformative moment for Spruce as we focus our expertise in rare disease on a potential near-te

      4/15/25 7:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Spruce Biosciences downgraded by JMP Securities

      JMP Securities downgraded Spruce Biosciences from Mkt Outperform to Mkt Perform

      12/11/24 8:25:53 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences downgraded by Oppenheimer

      Oppenheimer downgraded Spruce Biosciences from Outperform to Perform

      12/11/24 8:25:37 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences downgraded by Guggenheim

      Guggenheim downgraded Spruce Biosciences from Buy to Neutral

      3/14/24 8:20:07 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Charlton Ralph William Iii converted options into 164,750 shares and covered exercise/tax liability with 58,784 shares, increasing direct ownership by 191% to 161,339 units (SEC Form 4)

      4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

      12/20/24 8:30:02 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CFO Gharib Samir M. converted options into 229,750 shares and covered exercise/tax liability with 81,976 shares, increasing direct ownership by 73% to 350,550 units (SEC Form 4)

      4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

      12/20/24 8:28:58 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Szwarcberg Javier B. converted options into 559,500 shares and covered exercise/tax liability with 199,630 shares, increasing direct ownership by 335% to 467,191 units (SEC Form 4)

      4 - SPRUCE BIOSCIENCES, INC. (0001683553) (Issuer)

      12/20/24 8:28:11 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    SEC Filings

    See more
    • Spruce Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

      6/12/25 8:10:45 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Spruce Biosciences Inc.

      DEFA14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

      6/12/25 8:05:03 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Spruce Biosciences Inc.

      DEFA14A - SPRUCE BIOSCIENCES, INC. (0001683553) (Filer)

      6/6/25 4:10:04 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Leadership Updates

    Live Leadership Updates

    See more
    • Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

      Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underway for Cohort 3 in CAHptain Study for Pediatric Classic CAH Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2023 and provided corporate updates. "Our goal with the POWER study is to ass

      8/14/23 4:00:00 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Appoints Percival Barretto-Ko to Board of Directors

      Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Percival Barretto-Ko to the company's Board of Directors. Concurrently, Dina Chaya, Ph.D., has stepped down from the Board of Directors. "On behalf of Spruce, I am pleased to welcome Percival Barretto-Ko to our Board of Directors," said Mike Grey, Executive Chairman of Spruce Biosciences. "Percival is an accomplished and

      5/25/23 8:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates

      CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Achieves 50% Enrollment in CAHmelia-204 and Approaches 75% Enrollment in CAHmelia-203 Enrollment in P.O.W.E.R. Study for Polycystic Ovary Syndrome (PCOS) Complete – Topline Results Anticipated in Q3 2023 Cohort 1 for Phase 2 CAHptain Study in Pediatric Classic CAH Fully Enrolled Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates. "I am pleased by the meaningful pro

      5/15/23 8:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Financials

    Live finance-specific insights

    See more
    • Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

      Biologics License Application (BLA) Submission to U.S. FDA for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Anticipated in 1H 2026 Spruce to Host Conference Call Today at 8:30 a.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). "This is truly a transformative moment for Spruce as we focus our expertise in rare disease on a potential near-te

      4/15/25 7:00:00 AM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

      CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia (CAH) with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of Tildacerfont in Pediatric Classic CAH Supports Further Dose-Ranging Across Additional Dosing Cohorts Topline Results from CAHmelia-204 Study of Tildacerfont in Adult Classic CAH Evaluating Glucocorticoid (GC) Reduction Anticipated in Third Quarter of 2024 Resource Prioritization and Cost Reductions Extend Cash Runway Through End of 2025 Conference Call Today at 4:30 p.m. ET Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commerci

      3/13/24 4:08:00 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SPRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

      SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

      11/14/24 5:45:17 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

      SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

      11/14/24 4:39:47 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Spruce Biosciences Inc.

      SC 13G/A - SPRUCE BIOSCIENCES, INC. (0001683553) (Subject)

      11/12/24 4:10:36 PM ET
      $SPRB
      Biotechnology: Pharmaceutical Preparations
      Health Care